OCGN Jun 2024 3.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 03:43PM EDT. Market open.
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.1500 |
| Strike | 3.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.1000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 773 |
GlobeNewswireOcugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
- GuruFocus.com
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.
© 2024 Yahoo. All rights reserved.